Sign inJoin
Company / Finance

20/20 Biolabs, Inc.

AIDX · NASDAQ

20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.

FollowAdd to WatchlistAsk Question
NASDAQAIDXCoverage BootstrapDiagnosticsMulti-Cancer DetectionLaboratory Developed Tests
Latest ReportMay 15, 2026AIDX: OneTest has revenue growth, but the new Nasdaq float is dilution mathView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

AIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math

20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.

May 15, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
20/20 Biolabs, Inc.OneTest has revenue growth, but the new Nasdaq float is dilutionMay 15, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
AIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.NASDAQMay 15, 2026Research reportReadSlides